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ten men with normal coronary arteries. CFR (peak/basal mean velocity) was
measured, immediately after angioplasty, a few days, one month and four
months later, with a NO. 3F coronary Doppler catheter placed immediately
proximal to the lesion and an intracoronary injection of 12.5 mg papaverine.
All 16 patients had no coronary restenosis at follow up angiography.
Results: CFR and hemodynamic data (heart rate: HR (bpm). left ventricular
end-diastolic pressure: LVEDP (mmHg) are reported below. In patients with
AMI undergoing direct angioplasty, CFR showed slowly progressive improve-
ment after angioplasty. However, even after four months CFR was impaired
significantly as compared with CFR in the normal region.
immediately alewdays one month four months control
after later later later In = 10)
CFR 14± 0.3 1.8± 0.6' 25 ± 0.8** 2.9 ± 0.9'H 4.0 ± 10
HR 79 ± 12 78 ± 10 72 ± 10 71 ± 8 70 ± 5
LVEDP 23 ± 7 19± 7 16± 4' 16 ± 6' 10± 4
'P < 0.05,"P < 0.01 vs immediately after, +p < 001 YS control
Conclusion: In patients with acute myocardial infarction undergoing di-
rect angioplasty, impaired coronary flow reserve is present for at least one
month after coronary reperfusion. This "vascular stunning" must be consid-
ered when exercise tolerance in patients with acute myocardial infarction is
assessed within one month.
is depicted as low SI areas within high SI zone in risk area by Gd-MRI. Pa-
tients were classified into 2 groups according to duration from occlusion to
reperfusion (early reperfusion (ER) group less than 6 hour, late reperfusion
(LR) group more than 6 hour) and each group was classified into 2 subgroups
according to Gd-DTPA enhancement pattern (hemorrhagic (H) and non hem-
orrhagic (N) pattern I. Results are shown in Table.
Gd-MRI n(%) Duration 01 peak CK EF EF
occlusion (admission) (1 month)
ER H 4(28) 3.9 ± 0 4707 ± 913' 55 ± 11 54 ± 12'
N 14(72) 44± 1.1 1452 ± 896 53 ± 8 61 ± 10t
LR H 14(66) 20± 24 3412 ± 2100' 45 ± 10 47 ± 12'
N 21 (34) 24± 18 1458 ± 1413 52 ± 12 58 ± 9
EF: left ventricular ejection fraction, * P < 0.05 vs. non-hemorrhagic myocardial infarction,
t P< 0.05 Ys. EF (admission)
The incidence of AHMI was 28% in ER group and 66% in LR group.
AHMI demonstrated higher peak serum creatine kinase (CK) level and
poorer improvement of left ventricular function even in ER group than non-
hemorrhagic AMI. Conclusion: (1) Gd-MRI can only detect AHMI in vivo. (2)
AHMI occurs even in ER group. (3) The incidence of AHMI increase markedly
in LR group.
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Zatebradine is a memberof a new class of compounds, sinus node inhibitors,
that may be useful for the management of chronic stable angina. To test
this concept, 188 pts with mild to moderate angina in 17 Canadian centers
were enrolled in a parallel-design trial with placebo and diltiazem compari-
son groups; 143 of them completed a placebo run-in period that required
reproducible exercise-induced angina and ST depression. They were then
randomized to placebo, zatebradine or diltiazem SA. Study drugs were upti-
trated (2.5, 5 and 7.5 mg BID for zatebradine and 60, 90 and 120 mg BID for
diltiazem SR) at weekly intervals if the exercise test remained positive. The
highest dose was reached by 24 of 47 zatebradine pts and 28 of 49 diltiazem
pts. Pts took no other anti-anginal drugs except sublingual NTG to relieve
angina. The primary endpoint of the trial was the change from baseline in
total exercise time, measured at 12 hours post-dose, after at least 2 weeks
at the optimum dose. The table lists the differences from baseline, ±1 SD:
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20 ± 4
61 ± 11#
3.02 ± 0.25
Control
(n ~ 10)
27 ± 17 24 ± 7 29 ± 9
35 ± 22# 46 ± 13# 69 ± 19#
1.36 ± 0.28& 1.89 ± 0.31 & 246 ± 0.36&
L--* ----J l--*----J
After PTCA 2weeks 6 months
In ~ 11) In = 9) (n ~ 61
# P < 0.Q1 YS resting APV, &p < 001 YS control, 'p < 0.01
Time Course of Impaired Coronary Vasodilatory
Reserve After Reperfusion in Acute Myocardial
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We have previously reported that coronary vasodilatory reserve is severely
impaired immediately after reperfusion in patients with acute myocardial in-
farction. To investigate the time course of impaired coronary vasodilatory
reserve after reperfusion, we studied 11 patients with a first acute anterior
myocardial infarction who underwent coronary angioplasty (PTCA) within 6
hours after the onset of symptom. After PTCA, a coronary Doppler guide
wire was positioned beyond the infarct related coronary lesion. Dipyridamole
10.56 mglkg) was administered intravenously over 4 minutes and coronary
flow velocity was measured for 10 minutes. Coronary vasodilatory reserve
was calculated as the ratio of hyperemic average peak velocity (APV) I resting
APV These measurements were repeated at 2 weeks (n = 9) and 6 months
(n = 6) after PTCA. Additional 10 patients with normal angiograms served as
control.
Results:
Conclusion: Coronary vasodilatory reserve is severely impaired immedi-
ately after reperfusion. The coronaryvasodilatory reserve gradually improves
over 2 weeks but the impairement persists at 6 months after acute myocar-
dial infarction.
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There has been no data available on the incidence of acute hemorrhagic
myocardial infarction (AHMI) until now except for autopsied heart. The pur-
pose of this study is to evaluate the incidence of AHMI after reperfusion
therapy with Gd-DTPA enhanced MRI (Gd-MRII in beating heart. We stud-
ied 53 patients of acute myocardial infarction. All patients underwent suc-
cessful reperfusion therapy by PTCA on admission and ECG gated Gd-MRI
with 1.5 Tesla system within 1 week after reperfusion. 18 patients supple-
mented gradient echo acquisition (GEA) MRI. GEA MRI depicts hemorrhage
as low signal intensity (SI) zones due to paramagnetic susceptibility effect
of deoxyhemoglobin. Our preliminary study demonstrated that intramyocar-
dial hemorrhage was depicted as low SI areas within high SI zone in risk
area by Gd-MRI. The location of low SI areas by Gd-MRI corresponded to
low SI zones by GEA MRI and macroscopic intramyocardial hemorrhage in
autopsied heart. The definition of AHMI is the enhancement pattern which
The improvement in exercise time with diltiazem, but not with zatebradine,
was significantly better than with placebo. The number of responders, de-
fined as pts whose total exercise time improved by >20% or by >60 sec,
was higher with diltiazem Ip < 0.01), but not with zatebradine, compared
to placebo. Both drugs improved time to angina and time to 1 mm ST de-
pression. Visual phenomena, described as wavy lines or flashes in peripheral
visual fields, were reported by 26% of the zatebradine pts.
Conclusion: Although zatebradine has anti-anginal efficacy, as shown in
this trial, visual adverse effects will limit its clinical utility for this indication.
However, drugs like zatebradine that slow heart rate but have no other car-
diac effects may playa role in the management of angina.
[957-112 1 The Incidence and Clinical Implication of Acute
Hemorrhagic Myocardial Infarction Detected by
MRI
Completed Pts
Total exercise time (sec)
Time to angina (sec)
Time to t ST (sec)
Heart rate at rest (bpm)
*p < 0.05 versus placebo
Placebo
49
43 ± 56
30 ± 82
12 ± 94
o± 10
Zatebradine
47
56 ± 69
63 ± 76'
59 ± 87'
-13± 11*
Diltiazem
47
79 ± 56'
76 ± 65'
60 ± 90'
-6± 10'
